Given the above finding showing a promising anti-allergy effect of the Gal d2-mRNA vaccine, we further modified the vaccine modality by conjugating immune-suppressive cytokine IL-10 encoding mRNA with Gal d2-mRNA through a T2A self-cleaving peptide (Figure 2A). This evidence concerns the gene IL10 and allergic disease.